Here's Why Moderna's Growth May Be Just Getting Started
Moderna (NASDAQ: MRNA) stock might look a bit expensive these days. The shares have climbed more than 200% this year. And while the forward price-to-earnings ratio of 11 isn't too excessive -- it's much higher than its level of less than four earlier this year. At the same time, some investors wonder whether Moderna may have reached peak sales of its coronavirus vaccine. That's as more and more people get vaccinated and coronavirus cases decline.
Right now, it's too early to predict if and when coronavirus vaccine sales will slow. Experts say the virus will stick around. And we'll need protection. That means ongoing need for vaccines. So, it doesn't seem likely sales will drop off a cliff. But even if COVID-19 vaccine sales stagnate at some point in the future, Moderna investors should look ahead with optimism. Here's why I think Moderna's growth is just getting started...
Image source: Getty Images.
Source Fool.com
